In particular, KMT2A::AFF1 ALL, an aggressive leukemia with a poor prognosis and a low mutational burden, exhibits substantial transcriptional heterogeneity between individuals. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.